"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Descriptor ID |
D009103
|
| MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
| Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 4 | 1 | 5 |
| 2011 | 3 | 2 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 4 | 0 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 1 | 4 |
| 2021 | 5 | 0 | 5 |
| 2022 | 4 | 0 | 4 |
| 2023 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct; 13(5):261-268.
-
Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders. J Neurol Sci. 2023 08 15; 451:120693.
-
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730.
-
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. CNS Drugs. 2022 09; 36(9):977-993.
-
ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. Cell Rep. 2021 08 24; 36(8):109602.
-
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 07; 38(7):3724-3742.
-
IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12R?1 internalization and suppress EAE. Proc Natl Acad Sci U S A. 2020 09 01; 117(35):21557-21567.
-
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct; 267(10):2851-2864.
-
Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.
-
Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy. J Clin Neurosci. 2015 Oct; 22(10):1669-71.